Valley News – Sandra Wong, the William W. Coon Professor of Surgical Oncology and associate chairwoman of clinical affairs at the University of Michigan Health System, has been named chairwoman of surgery and senior vice president of the surgical service line at Dartmouth-Hitchcock and chairwoman of surgery at the Geisel School of Medicine at Dartmouth. Her term begins Oct. 26.

Valley News – Quotes Peter Mason, assistant professor of community and family medicine, on the announcement that Alice Peck Day Memorial Hospital will become Dartmouth-Hitchcock’s fifth affiliate, should the state approve the agreement the two institutions expect to file in September. Mason says he hopes that an affiliation would make patients’ transitions between the two hospitals “much more seamless and much more appropriate.”

The Boston Globe – Cites comments by Gregory Tsongalis, professor of pathology, from a meeting of the Massachusetts Biotechnology Council last month on how the differences in the molecular profiles of primary tumors and their metastases, and from one spot in a tumor to another, “speak to how little we know about this disease.”

MedPage Today – Quotes Elliot Fisher, director of the Dartmouth Institute for Heath Policy and Clinical Practice, who comments that a hospital or physician group were more likely to achieve savings the longer they had participated in Medicare Accountable Care Organizations (ACOs), which comprise hospitals, physicians groups, and other clinicians collaborating to coordinate care for all patients.

Wired – An opinion piece by Kendall Hoyt, assistant professor of medicine, which urges governments to invest in countermeasure programs that will allow for more speedy and efficient creation of vaccines that are outbreak ready before pandemics arise and spread. Hoyt argues that “medical countermeasure programs must focus not just on innovation but also on the timeliness of innovation. Once this becomes our goal, we will run faster in our race against pathogens.”

U.S. News & World Report – Geisel is listed among ranked institutions, and as one of three Ivy League schools, that interview the highest numbers of underrepresented applicants. A chart lists Geisel as having interviewed 231 minority students out of a total of 752 for fall 2014.

Business Insider – Quotes Lisa Schwartz, professor of medicine, on the drug flibanserin, marketed as a pink pill called Addyi, recently approved by the Food and Drug Administration after two failed attempts. Schwartz points out that despite what appeared to be feminist forces helping the approval along, the drug could be considered anti-feminist. “The strongest advocate for women would want good, safe drugs that will really help them,” she said.

WFTV – Highlights a randomized controlled study by Geisel and Dartmouth-Hitchcock researchers supporting the value and efficacy of the Emmi programs, a series of online presentations that makes complex medical information easy to understand, and uses plain language, animation and graphics to educate patients about upcoming surgery procedures, chronic conditions, and safety. Researchers found that patients who had viewed an Emmi program about their upcoming procedure had decreased anxiety, lower sedation medication requirements, and shorter procedure times.

MPR News – In an interview with Minnesota Public Radio, H. Gilbert Welch, professor of medicine at Geisel, and Dr. Jessica Herzstein of the U.S. Preventive Services Task Force, discuss the pros and cons of medical screening tests and early detection of diseases like cancer. Welch and Herzstein question whether early screening is worth the fear, anxiety, false alarms, and possible over-diagnosis, and say there’s not just a dollar cost, but a human cost.

Journal Telegraph – Steve Woloshin, professor of medicine, is among the experts who believe that Addyi, the first official “female Viagra,” was approved by the Food and Drug Administration’s under pressure from feminists. “It’s politicizing what should be a scientific judgment,” Woloshin states.